W942134 魁蒿(Artemisia princeps var orientalis)水提取液对几种植物种的异株克生效应[刊,英]/Kil,B.S.…∥Journal of Chemical Ecology.-1992,18(1).-39~51[WBTA,1992,9(6),5946]W942135 伏加尔霉素的除草活性及作用方式[刊,英]/Ba...W942134 魁蒿(Artemisia princeps var orientalis)水提取液对几种植物种的异株克生效应[刊,英]/Kil,B.S.…∥Journal of Chemical Ecology.-1992,18(1).-39~51[WBTA,1992,9(6),5946]W942135 伏加尔霉素的除草活性及作用方式[刊,英]/Babczinski,P.…∥Pesticide Science.-1991,33(4).-439~446[WBTA,1992,9(6),5934]W942136 新型生长阻滞剂展开更多
Idiopathic pulmonary arterial hypertension (IPAH) is a progressive, nearly fatal condition that until recently has had very few treatment options. Median survival time for untreated IPAH was 2.8 years without effect...Idiopathic pulmonary arterial hypertension (IPAH) is a progressive, nearly fatal condition that until recently has had very few treatment options. Median survival time for untreated IPAH was 2.8 years without effective drug intervention. IPAH is characterized by deregulated proliferation of pulmonary arterial endothelial and intimal smooth muscle cells resulting in progressive pulmonary vascular remodeling and an increase in pulmonary arterial pressure. In order to alleviate their symptoms, anticoagulants, diuretics, calcium channel blockers and inotropic agents have been used to treat patients with PAH. Moreover, specific targeted therapies using prostacyclins,展开更多
文摘W942134 魁蒿(Artemisia princeps var orientalis)水提取液对几种植物种的异株克生效应[刊,英]/Kil,B.S.…∥Journal of Chemical Ecology.-1992,18(1).-39~51[WBTA,1992,9(6),5946]W942135 伏加尔霉素的除草活性及作用方式[刊,英]/Babczinski,P.…∥Pesticide Science.-1991,33(4).-439~446[WBTA,1992,9(6),5934]W942136 新型生长阻滞剂
基金Acknowledgements This research program was supported by the National Natural Science Foundation of China (No. 81000018), Special Financial Grant from the China Postdoctoral Science Foundation (No. 201104776) and the Major Program of the Chinese PLA General Hospital Funds. (No. 10KMZ04).
文摘Idiopathic pulmonary arterial hypertension (IPAH) is a progressive, nearly fatal condition that until recently has had very few treatment options. Median survival time for untreated IPAH was 2.8 years without effective drug intervention. IPAH is characterized by deregulated proliferation of pulmonary arterial endothelial and intimal smooth muscle cells resulting in progressive pulmonary vascular remodeling and an increase in pulmonary arterial pressure. In order to alleviate their symptoms, anticoagulants, diuretics, calcium channel blockers and inotropic agents have been used to treat patients with PAH. Moreover, specific targeted therapies using prostacyclins,